Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience
- 554 Downloads
To clarify the toxicity of palliative radiotherapy (RT) and its efficacy against bleeding of unresectable gastric cancer.
Clinical data of 19 patients received palliative RT for bleeding from unresectable gastric cancer were reviewed. The median total dose and dose per fraction were 40 Gy (range 2–50 Gy) and 2.5 Gy (range 1.8–3 Gy).
The treatment success rate was 68.4%. By using a tumor alpha/beta ratio of 10, biological effective dose of 50 Gy10 or more was significantly correlated with treatment success (P = 0.040). The median event-free survival was 1.5 months after RT and the median overall survival from starting RT was 3.4 months. Grade 3 nausea and anorexia were recorded in 1 and 3 patients, respectively.
Palliative RT was effective for hemostasis in patients with gastric cancer bleeding with minor adverse events.
KeywordsGastric cancer Radiotherapy Bleeding Hemostasis
- Coia LR, Paul AR, Engstorm PF (1988) Combined radiation and chemotherapy as primary management of adenocarcinoma of esophagus and gastroesophageal junction. Cancer 61:643–649. doi: 10.1002/1097-0142(19880215)61:4<643::AID-CNCR2820610404>3.0.CO;2-4 PubMedCrossRefGoogle Scholar
- Hoskin PJ (1998) Radiotherapy in symptom management. In: Doyle D, Hanks GWC, Macdonald N (eds) Oxford textbook of palliative medicine, 2nd edn. Oxford University Press, New York, pp 278–280Google Scholar
- Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150. doi: 10.1200/JCO.2005.05.2308 PubMedCrossRefGoogle Scholar
- Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41. doi: 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P PubMedCrossRefGoogle Scholar